GSK Stock Analysis: GlaxoSmithKline | NYSE
Drug Manufacturers - General | NYSE, USA | Market Cap: 103.665m USD | 12M Return: 45.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 190M
EPS Trend: 96.6%
Qual. Beats: 9
Rev. Trend: 96.4%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
GSK plc is a UK-headquartered global pharmaceutical company that discovers, develops, manufactures, and commercializes vaccines, specialty medicines, and general medicines across the UK, the US, and international markets. The company operates through two segments: Commercial Operations and Total R&D, a structure that separates its sales and distribution activities from its drug discovery and development pipeline. Founded in 1715 and originally known as GlaxoSmithKline before rebranding to GSK in May 2022, it is among the longest-established players in the global pharmaceuticals industry.
Its portfolio spans specialty medicines in oncology, respiratory/immunology, and inflammation (including treatments for HIV, lupus, ovarian, and endometrial cancer); a broad vaccines franchise covering shingles, meningitis, RSV, influenza, hepatitis, HPV, and others; and general medicines addressing asthma, COPD, allergic rhinitis, and inflammatory skin conditions. As a large-cap health care company in the GICS Pharmaceuticals sub-industry, GSK competes in a sector characterized by long product development cycles, heavy R&D expenditure, and revenue dependence on patent-protected molecules and vaccine contracts. The company also pursues external innovation through partnerships, including an mRNA vaccine collaboration with CureVac and a TB therapy alliance with AN2 Therapeutics.
- Shingrix vaccine demand recovery lifts vaccine segment revenue
- ViiV HIV franchise margins expand as dolutegravir exclusivity holds
- Arexvy RSV vaccine faces Pfizer and Moderna competition in US market
| Net Income: 5.83b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 2.58 > 1.0 |
| NWC/Revenue: -18.78% < 20% (prev -11.24%; Δ -7.54% < -1%) |
| CFO/TA 0.10 > 3% & CFO 8.30b > Net Income 5.83b |
| Net Debt (21.4b) to EBITDA (11.3b): 1.90 < 3 |
| Current Ratio: 0.79 > 1.5 & < 3 |
| Outstanding Shares: last quarter (2.04b) vs 12m ago -1.52% < -2% |
| Gross Margin: 72.68% > 18% (prev 71.41%; Δ 1.27% > 0.5%) |
| Asset Turnover: 40.65% > 50% (prev 40.24%; Δ 0.42% > 0%) |
| Interest Coverage Ratio: 11.75 > 6 (EBIT TTM 8.13b / Interest Expense TTM 692.0m) |
| A: -0.07 (Total Current Assets 23.4b - Total Current Liabilities 29.6b) / Total Assets 82.9b |
| B: 0.18 (Retained Earnings 15.3b / Total Assets 82.9b) |
| C: 0.10 (EBIT TTM 8.13b / Avg Total Assets 80.6b) |
| D: 0.39 (Book Value of Equity 23.5b / Total Liabilities 59.9b) |
| Altman-Z'' = 1.20 = BB |
| DSRI: 1.04 (Receivables 10.5b/9.68b, Revenue 32.8b/31.5b) |
| GMI: 0.98 (GM 71.41% / 72.68%) |
| AQI: 1.04 (AQ_t 0.56 / AQ_t-1 0.54) |
| SGI: 1.04 (Revenue 32.8b / 31.5b) |
| TATA: -0.03 (NI 5.83b - CFO 8.30b) / TA 82.9b) |
| Beneish M = -2.96 (Cap -4..+1) = A |
As of July 23, 2026, the stock is trading at USD 50.76 with a total of 3,686,105 shares traded. Over the past week, the price has changed by -0.92%, over one month by +0.08%, over three months by -8.69% and over the past year by +45.53%.
Current recommended Stop Loss: 48.80 (which is 3.9% or 1.6 ATR below the current price).
GlaxoSmithKline has received a consensus analysts rating of 2.88. Therefore, it is recommended to hold GSK.
- StrongBuy: 1
- Buy: 0
- Hold: 5
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 58.1 | 14.4% |
Market Cap GBP = 77.5b (104b USD * 0.7472 USD.GBP)
P/E Trailing = 13.8027
P/E Forward = 21.692
P/S = 3.1624
P/B = 4.3988
P/EG = 19.5374
Revenue TTM = 32.8b GBP
EBIT TTM = 8.13b GBP
EBITDA TTM = 11.3b GBP
Long Term Debt = 14.0b GBP (from longTermDebt, last fiscal year)
Short Term Debt = 6.65b GBP (from shortTermDebt, last quarter)
Debt = 26.0b GBP (from shortLongTermDebtTotal, last quarter) + Leases 830.0m
Net Debt = 21.4b GBP (calculated: Debt 26.0b - CCE 4.54b)
Enterprise Value = 98.9b GBP (77.5b + Debt 26.0b - CCE 4.54b)
Interest Coverage Ratio = 11.75 (Ebit TTM 8.13b / Interest Expense TTM 692.0m)
EV/FCF = 15.86x (Enterprise Value 98.9b / FCF TTM 6.24b)
FCF Yield = 6.31% (FCF TTM 6.24b / Enterprise Value 98.9b)
FCF Margin = 19.02% (FCF TTM 6.24b / Revenue TTM 32.8b)
Net Margin = 17.78% (Net Income TTM 5.83b / Revenue TTM 32.8b)
Gross Margin = 72.68% ((Revenue TTM 32.8b - Cost of Revenue TTM 8.96b) / Revenue TTM)
Gross Margin QoQ = 75.42% (prev 69.17%)
Tobins Q-Ratio = 1.19 (Enterprise Value 98.9b / Total Assets 82.9b)
Interest Expense / Debt = 2.67% (Interest Expense 692.0m / Debt 26.0b)
Taxrate = 14.54% (1.08b / 7.44b)
NOPAT = 6.95b (EBIT 8.13b * (1 - 14.54%))
Current Ratio = 0.79 (Total Current Assets 23.4b / Total Current Liabilities 29.6b)
Debt / Equity = 1.10 (Debt 26.0b / totalStockholderEquity, last quarter 23.5b)
Debt / EBITDA = 1.90 (Net Debt 21.4b / EBITDA 11.3b)
Debt / FCF = 3.43 (Net Debt 21.4b / FCF TTM 6.24b)
Total Stockholder Equity = 20.5b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.23% (Net Income 5.83b / Total Assets 82.9b)
RoE = 28.47% (Net Income TTM 5.83b / Total Stockholder Equity 20.5b)
RoCE = 23.57% (EBIT 8.13b / Capital Employed (Equity 20.5b + L.T.Debt 14.0b))
RoIC = 11.91% (NOPAT 6.95b / Invested Capital 58.3b)
WACC = 5.66% (E(77.5b)/V(103b) * Re(6.80%) + D(26.0b)/V(103b) * Rd(2.67%) * (1-Tc(0.15)))
Discount Rate = 6.80% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -41.78 | Cagr: -0.47%
[DCF] Terminal Value 77.97% ; FCFF base≈5.29b ; Y1≈6.07b ; Y5≈8.93b
[DCF] Fair Price = 56.38 (EV 134b - Net Debt 21.4b = Equity 113b / Shares 2.00b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 96.64 | EPS CAGR: 8.55% | SUE: 2.65 | # QB: 9
Revenue Correlation: 96.40 | Revenue CAGR: 3.79% | SUE: 0.01 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.25 | Chg30d=+0.09% | Revisions=+0% | Analysts=2
EPS next Quarter (2026-09-30): EPS=1.43 | Chg30d=-1.22% | Revisions=-40% | Analysts=2
EPS current Year (2026-12-31): EPS=4.82 | Chg30d=-0.68% | Revisions=-40% | GrowthEPS=+2.3% | GrowthRev=+3.8%
EPS next Year (2027-12-31): EPS=5.16 | Chg30d=-1.57% | Revisions=-40% | GrowthEPS=+7.1% | GrowthRev=+5.1%
[Analyst] Revisions Ratio: -55% (up=1, down=7)